Opioid therapies and cytochrome P450 interactions

Journal of Pain and Symptom Management

Volumn 44, Issue 6 SUPPL., 2012, Pages

  Gudin, Jeffrey ^a  

^a ENGLEWOOD HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Adverse drug reactions; CYP2D6; CYP3A4; cytochrome P450; drug drug interactions; inducer; inhibitor; metabolism; opioids; prodrug; substrate

Indexed keywords

AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLARITHROMYCIN; CLOMIPRAMINE; CODEINE; CYTOCHROME P450; CYTOCHROME P450 2D6; DELAVIRDINE; DESIPRAMINE; DILTIAZEM; ERYTHROMYCIN; FENTANYL; FLUOXETINE; FLUVOXAMINE; HYDROCODONE; HYDROMORPHONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIPRAMINE; METHADONE; MORPHINE 3 GLUCURONIDE; OPIATE; OXYCODONE; RITONAVIR; SEROTONIN UPTAKE INHIBITOR; STEROID; TRAMADOL; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

ALLODYNIA; ARTICLE; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG OVERDOSE; DRUG TRANSFORMATION; FIRST PASS EFFECT; GENOTYPE; HUMAN; MYOCLONUS; NEUROTOXICITY; PAIN; PHENOTYPE; RESPIRATION DEPRESSION; SOMNOLENCE;

ANALGESICS, OPIOID; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; LIVER; MODELS, BIOLOGICAL; OPIOID-RELATED DISORDERS; PAIN;

EID: 84870905800     PISSN: 08853924     EISSN: 18736513     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2012.08.013     Document Type: Article

References (61)

1. Committee on Quality Heath Care in America, Institute of Medicine L.T. Kohn, J.M. Corrigan, and M.S. Donaldson To err is human: Building a safer health system 2000 National Academy Press Washington, DC
2. A.G. Winterstein, B.C. Sauer, C.D. Hepler, and C. Poole Preventable drug-related hospital admissions Ann Pharmacother 36 2002 1238 1248
3. T. Jacubeit, D. Drisch, and E. Weber Risk factors as reflected by an intensive drug monitoring system Agents Actions Suppl 29 1990 117 125
4. N.H. Ballentine Polypharmacy in the elderly: maximizing benefit, minimizing harm Crit Care Nurs Q 31 2008 40 45
5. J.H. Gurwitz, T.S. Field, and L.R. Harrold Incidence and preventability of adverse drug events among older persons in the ambulatory setting J Am Med Assoc 289 2003 1107 1116
6. T.A. Brennan, L.L. Leape, and N.M. Laird Incidence of adverse events and negligence in hospitalized patients: results of the Harvard Medical Practice Study I. 1991 Qual Saf Health Care 13 2004 145 151
7. American Society of Health-System Pharmacists (ASHP) Top patient concerns 2002: Omnibus survey results 2002 ASHP Bethesda, MD
8. D.J. Kelly, M. Ahmad, and S.J. Brull Preemptive analgesia I: physiological pathways and pharmacological modalities Can J Anaesth 48 2001 1000 1010
9. J.V. Pergolizzi Jr., S.A. Labhsetwar, and R.A. Puenpatom Exposure to potential CYP450 pharmacokinetic drug-drug interactions among osteoarthritis patients: incremental risk of multiple prescriptions Pain Pract 11 2011 325 336
10. J.V. Pergolizzi Jr., S.A. Labhsetwar, and R.A. Puenpatom Prevalence of exposure to potential CYP450 pharmacokinetic drug-drug interactions among patients with chronic low back pain taking opioids Pain Pract 11 2011 230 239
11. J.V. Pergolizzi, R.B. Raffa, and E. Gould Considerations on the use of oxymorphone in geriatric patients Expert Opin Drug Saf 8 2009 603 613
12. N. Attal, G. Cruccu, and R. Baron EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision Eur J Neurol 17 2010 1113 e1188
13. R. Chou, G.J. Fanciullo, and P.G. Fine Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain J Pain 10 2009 113 130
14. Federation of State Medical Boards of the United States Inc Model policy for the use of controlled substances for the treatment of pain J Pain Palliat Care Pharmacother 19 2005 73 78
15. J. Pergolizzi, R.H. Boger, and K. Budd Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone) Pain Pract 8 2008 287 313
16. C. Quigley Hydromorphone for acute and chronic pain Cochrane Database Syst Rev 1 2002 CD003447
17. H.S. Smith Opioid metabolism Mayo Clin Proc 84 2009 613 624
18. E.A. Hartshorn DRUG INTERACTION 2. How drugs interact Ann Pharmacother 40 2006 542 549
19. G.R. Wilkinson Drug metabolism and variability among patients in drug response N Engl J Med 352 2005 2211 2221
20. E. Kadiev, V. Patel, and P. Rad Role of pharmacogenetics in variable response to drugs: focus on opioids Expert Opin Drug Metab Toxicol 4 2008 77 91
21. J.F. Rogers, A.N. Nafziger, and J.S. Bertino Jr. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs Am J Med 113 2002 746 750
22. S.F. Zhou, C.C. Xue, X.Q. Yu, C. Li, and G. Wang Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring Ther Drug Monit 29 2007 687 710
23. D.A. Flockhart Drug interactions: P450 drug interaction table 2007 Indiana University Division of Clinical Pharmacology Indianapolis, IN Available from http://medicine.iupui.edu/clinpharm/ddis/table.aspx Accessed November 3, 2011
24. M.R. Hutchinson, A. Menelaou, D.J. Foster, J.K. Coller, and A.A. Somogyi CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes Br J Clin Pharmacol 57 2004 287 297
25. G. Andersen, L. Christrup, and P. Sjogren Relationships among morphine metabolism, pain and side effects during long-term treatment: an update J Pain Symptom Manage 25 2003 74 91
26. K. Hemstapat, G.R. Monteith, D. Smith, and M.T. Smith Morphine-3-glucuronide's neuro-excitatory effects are mediated via indirect activation of N-methyl-D-aspartic acid receptors: mechanistic studies in embryonic cultured hippocampal neurones Anesth Analg 97 2003 494 505
27. U.M. Stamer, and F. Stuber The pharmacogenetics of analgesia Expert Opin Pharmacother 8 2007 2235 2245
28. B. Mannheimer, and E. Eliasson Drug-drug interactions that reduce the formation of pharmacologically active metabolites: a poorly understood problem in clinical practice J Intern Med 268 2010 540 548
29. J. Grönlund, T.I. Saari, and N.M. Hagelberg Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone Br J Clin Pharmacol 70 2010 78 87
30. A. Pilotto, D. Seripa, and M. Franceschi Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms Gastroenterology 133 2007 465 471
31. C.J. Vecht, G.L. Wagner, and E.B. Wilms Interactions between antiepileptic and chemotherapeutic drugs Lancet Neurol 2 2003 404 409
32. R. Terlinden, J. Ossig, F. Fliegert, C. Lange, and K. Göhler Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects Eur J Drug Metab Pharmacokinet 32 2007 163 169
33. M. Adams, H.J. Pieniaszek Jr., A.R. Gammaitoni, and H. Ahdieh Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways J Clin Pharmacol 45 2005 337 345
34. W. Fiske, I. Benedek, and H. Ahdieh (241) Bioavailability of oxymorphone extended-release tablets following consumption of alcohol or food J Pain 9 4, Suppl 2 2008 36
35. L.R. Webster, S. Cochella, and N. Dasgupta An analysis of the root causes for opioid-related overdose deaths in the United States Pain Med 12 Suppl 2 2011 S26 S35
36. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, and F.P. Guengerich Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians J Pharmacol Exp Ther 270 1994 414 423
37. X. Song, H. Varker, and M. Eichelbaum Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome P450 isoenzymes Lung Cancer 74 2011 103 111
38. P. Madadi, D. Hildebrandt, and I.Y. Gong Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions Pediatrics 126 2010 e986 e989
39. G.L. Holmquist Opioid metabolism and effects of cytochrome P450 Pain Med 10 Suppl 1 2009 S20
40. J.H. Lin, and A.Y. Lu Interindividual variability in inhibition and induction of cytochrome P450 enzymes Annu Rev Pharmacol Toxicol 41 2001 535 567
41. Oxycontin [package insert] 2010 Purdue Pharma LP Stamford, CT
42. U.S. Food and Drug Administration. Blueprint for prescriber continuing education program. 2011. Available from http://www.fda.gov/downloads/drugs/ drugsafety/informationbydrugclass/ucm277916.pdf. Accessed April 18, 2012.
43. M.A. Kall, and J. Clausen Dietary effect on mixed function P450 1A2 activity assayed by estimation of caffeine metabolism in man Hum Exp Toxicol 14 1995 801 807
44. N. Hakooz, and I. Hamdan Effects of dietary broccoli on human in vivo caffeine metabolism: a pilot study on a group of Jordanian volunteers Curr Drug Metab 8 2007 9 15
45. S. Zhou, Y. Gao, and W. Jiang Interactions of herbs with cytochrome P450 Drug Metab Rev 35 2003 35 98
46. D.J. Greenblatt, R.A. Leigh-Pemberton, and L.L. von Moltke In vitro interactions of water-soluble garlic components with human cytochromes p450 J Nutr 136 3 Suppl 2006 806S 809S
47. B. Girennavar, G.K. Jayaprakasha, and B.S. Patil Potent inhibition of human cytochrome P450 3A4, 2D6, and 2C9 isoenzymes by grapefruit juice and its furocoumarins J Food Sci 72 2007 C417 C421
48. A.A. Izzo Drug interactions with St. John's Wort (Hypericum perforatum): a review of the clinical evidence Int J Clin Pharmacol Ther 42 2004 139 148
49. B.J. Gurley, S.F. Gardner, and M.A. Hubbard Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba Drugs Aging 22 2005 525 539
50. J. Lötsch, C. Skarke, J. Liefhold, and G. Geisslinger Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives Clin Pharmacokinet 43 2004 983 1013
51. C.F. Samer, Y. Daali, and M. Wagner The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone Br J Pharmacol 160 2010 907 918
52. T.N. Andreassen, I. Eftedal, and P. Klepstad Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study Eur J Clin Pharmacol 68 2012 55 64
53. Wellcome Trust Case Control Consortium N. Craddock, M.E. Hurles, and N. Cardin Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls Nature 464 2010 713 720
54. International HapMap Consortium A haplotype map of the human genome Nature 437 2005 1299 1320
55. International HapMap Consortium K.A. Frazer, D.G. Ballinger, and D.R. Cox A second generation human haplotype map of over 3.1 million SNPs Nature 449 2007 851 861
56. R. Mirnezami, J. Nicholson, and A. Darzi Preparing for precision medicine N Engl J Med 66 2012 489 491
57. H. Wynne Drug metabolism and ageing J Br Menopause Soc 11 2005 51 56
58. D.L. Schmucker Liver function and phase I drug metabolism in the elderly: a paradox Drugs Aging 18 2001 837 851
59. H.S. Smith The metabolism of opioid agents and the clinical impact of their active metabolites Clin J Pain 27 2011 824 838
60. R.D. Lindeman, J. Tobin, and N.W. Shock Longitudinal studies on the rate of decline in renal function with age J Am Geriatr Soc 33 1985 278 285
61. J.W. Rowe, R. Andres, J.D. Tobin, A.H. Norris, and N.W. Shock The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study J Gerontol 31 1976 155 163